Finapel

Quick links to important sections

Finapel

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Finapel

Property Description
Active ingredient Finasteride
Form Oral tablet
Pharmacological class 5-Alpha Reductase Inhibitor
General action Reduces Dihydrotestosterone (DHT) levels
Origin Synthetic Azasteroid compound

Finapel: Defining its Identity and Pharmaceutical Class

Finapel is a pharmaceutical preparation containing the active ingredient Finasteride, a compound classified pharmacologically as a 5-Alpha Reductase Inhibitor (5ARI). As an oral tablet intended for systemic use, Finapel is one of the commercially available options utilizing this compound, which is chemically recognized as a synthetic Azasteroid.

The classification as a 5-Alpha Reductase Inhibitor is clinically recognized for its unique ability to modulate hormone metabolism. This class of drug is often highlighted in pharmacological studies for providing a targeted approach to conditions associated with elevated androgen activity. Finasteride achieves this by selectively binding to and blocking the Type II isoform of the 5-alpha reductase enzyme.

Composition, Origin, and Form of Finasteride

The Finapel preparation is provided as a single-ingredient product, containing the synthetically derived active agent, Finasteride, along with necessary pharmaceutical excipients. This medication is specifically positioned for use in adult males requiring systemic management of hormone-driven conditions.

Being an oral therapy, Finapel is absorbed into the bloodstream, where it produces a sustained systemic effect. This controlled oral delivery system facilitates the maintenance of consistent drug levels needed for effective therapeutic action, a property supported by pharmacological evidence.

General Purpose: Reducing Dihydrotestosterone (DHT)

The primary biological purpose of Finasteride is the purposeful and significant reduction of the circulating concentration of the potent androgen dihydrotestosterone (DHT). It achieves this by impeding the metabolic conversion of the less potent hormone, testosterone, into DHT.

By consistently lowering the body's concentration of DHT, Finasteride removes a key biological stimulus that drives the growth or progression of certain hormone-sensitive tissues. This foundational mechanism is essential for its utility in managing conditions associated with the over-activity of dihydrotestosterone, such as the enlargement of prostate tissue.

Regulatory References

  1. Finasteride
  2. 5-Alpha Reductase Inhibitor
  3. Azasteroid
  4. oral therapy
  5. dihydrotestosterone (DHT)

What side effects are possible with Finapel?

Possible Side Effects and Safety Information

The officially documented safety profile for Finapel (Finasteride) is characterized by adverse reactions primarily categorized by frequency and the organ systems they involve. These classifications are based strictly on regulatory sources like the FDA and EMA Summary of Product Characteristics (SmPC).

Frequency and System-Organ Classes

The most commonly reported adverse reactions are related to the Reproductive system and breast disorders and the Psychiatric disorders.

Classification Adverse Reactions System-Organ Class (SOC)
Common Decreased libido, Erectile dysfunction (Impotence) Reproductive/Psychiatric
Uncommon Ejaculation disorder, Breast enlargement, Depressed mood, Rash Reproductive/Psychiatric/Dermatological
Not Known Persistence of sexual dysfunction (after discontinuation), Male breast cancer, Suicidal ideation, Testicular pain, Angioedema Various (Neoplasms, Immune, Reproductive)

Serious Adverse Reactions and Key Constraints

The regulatory documents highlight certain serious adverse reactions. These include the documented association with Male Breast Cancer and the reported risk of high-grade Prostate Cancer (specifically observed with the higher 5 mg dose). Serious hypersensitivity reactions, such as Angioedema, and Suicidal Ideation are also noted concerns.

Finapel is contraindicated for use in pregnant or potentially pregnant women due to the risk of fetal abnormalities. Furthermore, the medication causes a decrease in Prostate Specific Antigen (PSA) concentrations, a constraint that requires the interpretation of PSA test results to be adjusted for accurate prostate health monitoring.

Overdose and Emergency Response

Overdose Scope

Documented Overdose Presentations: The official prescribing information for Finapel (Finasteride) indicates a wide margin of safety regarding acute overexposure. Human clinical studies have documented that patients who ingested single doses up to 400 mg, and those who received multiple doses up to 80 mg per day for three months, did not report adverse effects explicitly linked to the excessive dose. This high tolerance means that an acute, specific overdose syndrome has not been formally defined based on human data.

Emergency-Response Statements: If Finapel overdose is suspected, immediate medical attention must be sought. This requirement stands regardless of whether specific adverse symptoms are apparent following ingestion.

Overdose-Context Constraints: Regulatory authorities confirm that no specific antidote is known or available for Finasteride overexposure. Therefore, the required clinical management strategy is strictly defined as providing symptomatic and supportive care, with medical procedures applied according to the patient’s clinical status.

Resulting Overdose Structure

Official overdose statements:

  • Acute adverse effects were not reported in human studies involving ingestion of single doses significantly exceeding the therapeutic amount.
  • Immediate medical evaluation is required if an overdose is suspected.
  • Treatment for overexposure is limited to symptomatic and supportive measures.

Connection to the overall overdose profile: The official overdose profile is characterized by a high documented human tolerance, where high dose exposure did not result in acute clinical manifestation. However, the regulatory documentation mandates that immediate medical help be sought when overdose is suspected because there is no specific antidote known, necessitating supportive management under clinical supervision.

Therapeutic Uses of Finapel

Finapel (Finasteride) is a prescription medicine generally used in men to manage two distinct health conditions, addressing both chronic symptomatic discomfort and structural changes. It is applied across domains where additional symptomatic support is needed to help ease the overall symptom burden.

The medication is commonly used to help with conditions characterized by periods of heightened symptoms that create noticeable physiological strain, primarily Male Pattern Hair Loss (MPHL) and Benign Prostatic Hyperplasia (BPH), or enlarged prostate.

Managing Male Pattern Hair Loss

This therapeutic domain focuses on the gradual thinning and loss of hair on the scalp. Finapel supports the patient during these phases by helping to slow the progression of hair loss and may assist with preserving hair coverage, which contributes to a sense of stability regarding their appearance.


Addressing Urinary Symptoms from Enlarged Prostate

Finapel is relevant for easing symptoms associated with BPH, a condition where the prostate gland enlarges. This therapeutic use is applied to manage a group of disruptive symptoms, such as frequent, difficult, or hesitant urination, providing supportive relief that assists patients with coping more steadily with these episodes.

Quick Fact: Support for Urinary Symptoms : Finapel contributes to the goal of functional stability in conditions involving episodic or fluctuating manifestations of BPH.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Finapel — official regulatory information

Eligibility scope

Category Official Regulatory Statement
Populations for whom use is allowed: Adult Males (18 years and older).
Populations for whom use is not recommended: Pediatric patients (under 18 years).
Populations for whom use is contraindicated: Women, females who are or may potentially be pregnant, and individuals with known hypersensitivity to any component.

Age and Condition-Specific Eligibility Rules

  • Pediatric Use: Safety and effectiveness have not been established in patients under 18 years of age.
  • Geriatric Use: No dosage adjustment is necessary for older adults.
  • Renal Impairment: No dosage adjustment is necessary in patients with renal insufficiency.
  • Liver Function: Caution should be exercised in the administration of Finapel to patients with liver function abnormalities.
  • Handling Restriction: Women who are or may potentially be pregnant must not handle crushed or broken tablets.

Connection to the overall eligibility profile

Regulatory documents define the eligibility profile for this medication with clear restrictions based on gender, age, and reproductive status. The stringent criteria indicate Finapel exclusively for adult males, with its use formally prohibited for all women and unestablished for the pediatric population. The official labeling additionally requires that caution be applied when administering Finapel to patients with impaired liver function.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Finapel

Interaction Scope

Medicinal product categories with documented interactions: None explicitly documented as clinically important.

Specific interacting medicines (if explicitly listed): Antipyrine, Digoxin, Propranolol, Theophylline, and Warfarin. These compounds were tested in clinical studies and no clinically important interactions were identified upon co-administration.

Mechanistic basis of interactions (only if stated in label): The drug is metabolized primarily via the Cytochrome P450 3A4 (CYP3A4) enzyme, but it does not appear to affect the P450-linked drug-metabolizing enzyme system.

Timing-based interaction rules (if applicable): None. Co-administration with food does not influence the bioavailability of the active ingredient.

Population-specific interaction notes (if applicable): Caution is noted for patients with liver function abnormalities because the drug is extensively metabolized in the liver, and the effect of hepatic insufficiency on pharmacokinetics has not been formally studied.

Interaction-related restrictions: None explicitly listed as a drug-drug restriction or formal contraindication in regulatory interaction sections.


Interaction Classifications (High-Level)

Interaction severity classification (as defined in official documents): Absence of clinically important interactions with tested agents.

Regulatory basis (EMA / FDA / etc.): Finasteride interaction studies documented in official government prescribing information.

Interaction-context constraints (as defined in official documents): The limited data available regarding patients with liver function abnormalities results in an official caution in this population.

Resulting Interaction Structure

Official interaction statements:

  • No clinically important drug interactions have been identified in studies with specific co-administered agents.
  • The drug is primarily cleared via the CYP3A4 metabolic pathway, but it does not appear to affect this or other P450 systems.
  • Co-administration with food is not associated with a clinically significant alteration of the drug's bioavailability.
  • The official prescribing information notes caution in co-administration for patients with liver function abnormalities.

Connection to the overall interaction profile (2–4 sentences): Official regulatory documents define Finapel's interaction structure by primarily documenting the absence of clinically significant interactions with other medicines that were studied. This finding is supported by regulatory evidence that the active ingredient does not appear to affect the major P450 enzyme system, which is a common cause of drug-drug interactions. The only specific constraint is the caution associated with use in patients with liver function abnormalities, which reflects limited pharmacokinetic data in this specific population.

Mechanism of Action

Finapel's active ingredient, Finasteride, acts as a selective, competitive, and time-dependent inhibitor of the enzyme 5-Alpha Reductase (5AR) Type II Isoenzyme. This enzyme catalyzes the metabolic conversion of Testosterone into the potent androgen, Dihydrotestosterone (DHT).

The drug binds specifically to 5AR Type II, forming a stable complex that functionally inactivates the enzyme and blocks the pathway. This enzymatic inhibition initiates a hormonal cascade shift, causing a systemic and tissue-level decrease in DHT concentration (typically suppressed by 70–80%), alongside a compensatory increase in circulating Testosterone.

This reduction in the primary proliferative stimulus leads to tissue-specific androgen deprivation. The subsequent cellular response is a gradual shift toward decreased cell count and cellular atrophy in target tissues. The mechanism is highly specific to the Type II isoform and is reversible, necessitating continuous presence to maintain the inhibitory action.

Dosage and Administration Information

How Finapel is Used

Finapel is an oral medication utilized in clinical practice through specific, administration patterns. It is supplied as film-coated tablets in two distinct strengths, where the choice of dose is directly correlated with the approved therapeutic application.

Official Dosing and Administration

The fundamental principle for using Finapel is once-daily administration. The tablet must be taken orally and swallowed whole. Consistent daily use is necessary, as the drug's effect is only maintained through continuous presence in the bloodstream.

Use Pattern Standard Labeled Daily Dose
Prostate Management (BPH) One 5 mg tablet
Hair Loss Management (MPHL) One 1 mg tablet

Administration Guidelines and Duration

Finapel tablets can be taken with or without food, providing flexibility in the daily schedule. To ensure correct use, the tablet should not be crushed, broken, or divided, a procedural constraint noted in official labeling. Should a dose be missed, the official instruction is to simply resume the regular schedule by taking the next dose as planned; a double dose should not be taken to compensate.

Treatment is defined as a long-term commitment. For prostate management, continuous daily administration over several months is often required before an assessment can be made. For hair loss management, continued use is necessary to sustain the benefit, as discontinuation results in a gradual reversal of the effect over time. No dosage adjustment is typically required for older adults or patients with renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Early Research and Mechanisms

Research has explored whether the medication is associated with a change in symptom scores. Initial trials evaluated whether the medication affects motor function and pain levels. Some studies have examined the effect of nighttime administration and early symptom changes.


Head-to-Head and Long-Term Data

Comparative studies have been conducted to evaluate the medication versus other available treatments. The available evidence remains limited regarding long-term clinical changes beyond one year, and findings were mixed in some areas. Further research is necessary to clarify outcomes over several years.


Specific Population Studies

Clinical trials have included studies in pediatric populations. Research has evaluated whether combination use is associated with long-term clinical changes. Research evaluating the medication in pregnant populations is limited, and research examined the effects in a limited number of patients with kidney or liver impairment.

Frequently Asked Questions (FAQ)

Common questions about Finapel (FAQ)

Q: Why is Finapel also known by a different name?

The active ingredient in Finapel is Finasteride, a compound often sold under different brand names globally. These differences in naming are typically due to the specific dose (e.g., 1mg versus 5mg tablets) and the authorized use for which the drug is being marketed. Official product information often refers to the generic compound, Finasteride.

Q: Does Finapel work for all people who take it?

Official studies indicate that the medication has demonstrated effectiveness in treating symptoms for a significant proportion of men. However, like most treatments, it is not guaranteed to work for everyone. Individual responses may vary, and a commitment to continued treatment is necessary to assess the full benefit.

Q: How quickly do doctors usually see results from Finapel?

Official information states that visible results take time to appear. For hair loss, visible changes usually require at least three months of continuous daily use. For BPH (prostate symptoms), official information states that initial improvements often begin within the first few months of treatment.

Q: When can the full benefit of Finapel be expected?

The full therapeutic benefit is gradual and depends upon continued, sustained use. For prostate symptoms (BPH), maximum clinical benefit is typically achieved by six months. For hair loss, evidence indicates that the maximum therapeutic effect may continue to improve throughout the first one to two years of continuous use.

Q: What does the research say about long-term use of Finapel?

Long-term studies have evaluated the medication's profile over time. Some research reports have noted potential associations with long-term use and metabolic changes, including insulin resistance or type 2 diabetes. The safety and effectiveness for BPH have been studied over 6–10 years.

Q: Is blood testing typically required while taking Finapel?

The medication is known to reduce levels of Prostate Specific Antigen (PSA), a marker used to screen for prostate health. For accurate monitoring, official guidelines describe the need for the measured PSA value to be mathematically adjusted (such as by doubling the result) after a year of treatment.

Q: Can Finapel cause weight gain?

While not listed among the most common adverse reactions, regulatory reports have cited instances of unusual weight changes. Less common side effects reported have included both weight gain and weight loss, including cases of rapid weight gain.

Q: Are the side effects of Finapel permanent?

For most patients, side effects generally resolve upon stopping the medication. However, official post-marketing reports have indicated that some adverse reactions, such as sexual dysfunction (like erectile dysfunction), may persist in certain individuals after discontinuation of treatment.

Q: How long do common side effects from Finapel usually last?

Based on clinical data, many of the commonly reported side effects, such as those related to sexual function, are observed to decrease after the first year of continuous use. For most patients, these effects typically resolve upon discontinuation of the medication.

Q: Does Finapel make you tired or sleepy?

Official summaries of undesirable effects list somnolence, which is the medical term for unusual drowsiness or sleepiness. This is not a frequently occurring reaction, but it has been reported as a less common side effect.

Q: Can Finapel be stopped suddenly, or is tapering generally required?

Regulatory documents do not specify a tapering schedule for stopping the medication. However, because Finapel is intended for continuous treatment, official information indicates that discontinuation will lead to a gradual reversal of the therapeutic benefit over time.

Q: Does taking Finapel impact ability to drive or operate machinery?

The medication is generally not expected to impair the ability to drive or use machinery. However, due to reported side effects such as dizziness and drowsiness, patients are cautioned to assess their individual reaction to the medication before engaging in activities that require focus, such as driving.

Q: Does Finapel affect liver enzymes?

Regulatory information indicates that the active ingredient is extensively processed by the liver. Clinical trials have found a low rate of temporary and mild elevations in liver enzymes, known as serum aminotransferases. These changes were generally transient and did not require changes in medication use.

Q: Can I take Finapel with common pain relievers like ibuprofen?

Official interaction studies concluded that there are no clinically important interactions with tested medicines. Furthermore, the active ingredient does not appear to affect the main P450 enzyme system often responsible for drug interactions. This profile suggests a low risk of interaction with most standard over-the-counter pain relievers.

Q: Does Finapel interact with alcohol?

Official product information does not include a formal warning against consuming alcohol while taking the medication. However, some sources note that excessive alcohol use may affect the medication’s protective effect against low-grade prostate cancer and can potentially worsen sexual side effects.

Q: Is it safe to take over-the-counter supplements, like vitamins, while on Finapel?

The medication's mechanism suggests a low risk of interaction with standard vitamin and mineral supplements. Regulatory studies concluded that there are no clinically important interactions with the specific medicinal agents that were tested, as it does not affect the major P450 enzyme pathway.

Q: Does Finapel interact with common psychiatric medications?

Post-marketing surveillance has identified a risk of neuropsychiatric side effects, including reports of depression and suicidal ideation. While specific drug-drug interactions are not detailed in the official documents, this known neuropsychiatric side effect is a factor for consideration when the patient is also taking psychiatric medications.

Q: Can Finapel be taken with blood pressure medication?

Caution is noted in official documentation regarding co-administration with certain blood pressure medications. Specifically, when used with an alpha blocker, there is a potential for an increased risk of orthostatic hypotension, which is a drop in blood pressure upon standing up.

Q: Can a person with diabetes take Finapel?

The medication has no direct known effect on blood sugar levels. However, some research has suggested that the long-term use of the active ingredient may be associated with an increased risk of developing metabolic dysfunctions, such as insulin resistance or Type 2 diabetes.

Q: Is Finapel a new medication or has it been around for a while?

The active ingredient in Finapel has been available for clinical use for several decades, having received its initial FDA approval in the late 1990s. This history provides extensive regulatory oversight regarding its use and safety profile over time.

Q: What are the main clinical trials that support the use of Finapel?

The key evidence supporting the use of the medication comes from major, multi-year, placebo-controlled clinical trials. These studies include the PLESS trial for BPH and long-term trials that measured parameters like hair count and photographic assessment for male pattern hair loss.

How should Finapel be stored and disposed of?

How to Store and Dispose of Finasteride (Finapel)

Finasteride tablets must be stored at room temperature, generally between 15 C and 30 C (59 F and 86 F). The medicine must be kept in its original package to ensure protection from moisture and direct light.

Handling and Safety

The tablets must be stored out of the sight and reach of children.

A critical, labeled instruction is that women who are pregnant or may potentially be pregnant must not handle crushed or broken Finasteride tablets.

Disposal

Expired or unused Finasteride must be disposed of in accordance with local requirements. The medication must not be thrown away via household waste or flushed down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Finapel found in:

A-Z Index: